Funding for this research was provided by:
European Regional Development Fund (100523073)
Deutsche Forschungsgemeinschaft (INST 268/387-1)
Received: 1 November 2021
Accepted: 24 February 2022
First Online: 19 March 2022
: The investigations represent parts of the analyzes in the COVID genetics cohort Leipzig-Chemnitz, which was approved by the Institutional Review Board of Leipzig University (reference numbers 195/20-ek and EK-allg-37/10-1).
: Not applicable.
: MS receives funding from Pfizer Inc. for a project not related to this research. JL, SMS, and FF are employees of Adversis Pharma GmbH. JG is cofounder and CEO of Adversis Pharma GmbH. All other authors declare that they have no competing interests.